Core Viewpoint - Haofan Bio experienced a 5.23% increase in stock price, reaching 58.20 CNY per share, with a trading volume of 116 million CNY and a turnover rate of 4.82%, resulting in a total market capitalization of 6.286 billion CNY [1] Company Overview - Suzhou Haofan Bio Co., Ltd. is located at Changting Road 1, Suzhou High-tech Zone, Jiangsu Province, and was established on December 2, 2003. The company went public on July 12, 2023. Its main business involves the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks [1] Shareholder Information - Among the top ten circulating shareholders of Haofan Bio, a fund under Huatai PineBridge holds a position. The Huatai Medical and Health Mixed Fund (470006) entered the top ten circulating shareholders in the second quarter, holding 602,500 shares, which accounts for 1.5% of the circulating shares. It is estimated that the fund has earned approximately 1.7411 million CNY in floating profit today [2] - The Huatai Medical and Health Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.358 billion CNY. Year-to-date returns stand at 35.59%, ranking 1703 out of 8254 in its category; the one-year return is 41.87%, ranking 3403 out of 8037; and since inception, the return is 171.31% [2] - The fund manager of Huatai Medical and Health Mixed Fund (470006) is Zheng Lei, who has a cumulative tenure of 10 years and 262 days. The total asset scale under his management is 7.072 billion CNY, with the best fund return during his tenure being 53.42% and the worst being -21.99% [2]
昊帆生物股价涨5.23%，汇添富基金旗下1只基金位居十大流通股东，持有60.25万股浮盈赚取174.11万元